"RIV/00216208:11110/11:9069!RIV12-MSM-11110___" . . . . . "5"^^ . . "C-peptid je spojovac\u00ED m\u016Fstek A a B \u0159et\u011Bzce inzulinu a je po enzymatick\u00E9m roz\u0161t\u011Bpen\u00ED vylu\u010Dov\u00E1n v podob\u011B 31 aminokyselinov\u00E9ho \u0159et\u011Bzce do ob\u011Bhu v ekvimol\u00E1rn\u00EDm mno\u017Estv\u00ED s inzulinem. S\u00E9rov\u00E1 hladina C-peptidu v plazm\u011B je nez\u00E1visl\u00E1 na pod\u00E1n\u00ED exogenn\u00EDho inzulinu a neinterferuje ani s autoprotil\u00E1tkami, kter\u00E9 se proti n\u011Bmu vytv\u00E1\u0159\u00ED, a proto je pro diagnostick\u00E9 \u00FA\u010Dely jeho stanoven\u00ED, oproti inzulinu, mnohem spolehliv\u011Bj\u0161\u00ED a p\u0159esn\u011Bj\u0161\u00ED. Toto p\u016Fvodn\u00ED jedin\u00E9 vyu\u017Eit\u00ED C-peptidu v diagnostice dnes dopl\u0148uje znalost o jeho endogenn\u00EDch \u00FA\u010Dinc\u00EDch. C-peptid m\u016F\u017Ee ovliv\u0148ovat stupe\u0148 a m\u00EDru rozvoje c\u00E9vn\u00EDch a nervov\u00FDch komplikac\u00ED, jeho vy\u0161\u0161\u00ED hladina br\u00E1n\u00ED endoteli\u00E1ln\u00ED dysfunkci a m\u00E1 i analgetick\u00E9 \u00FA\u010Dinky. Tyto p\u0159\u00EDm\u00E9 a nep\u0159\u00EDm\u00E9 efekty rozv\u00EDj\u00ED \u00FAvahy o mo\u017En\u00E9m l\u00E9\u010Debn\u00E9m vyu\u017Eit\u00ED. V roce 2010 byla autoritami v diabetologii zve\u0159ejn\u011Bna nov\u00E1 doporu\u010Den\u00ED pro diagnostiku a screening, kter\u00E1 reflektuj\u00ED celosv\u011Btovou pandemii t\u00E9to choroby, v\u010Detn\u011B incidence morbidity, vynucen\u00E9 invalidity a mortality. P\u0159ehled ukazuje i mo\u017Enosti vyu\u017Eit\u00ED C-peptidu"@cs . . . "C-peptide: from diagnosis to clinical application"@en . "C-peptide: from diagnosis to clinical application"@en . "CZ - \u010Cesk\u00E1 republika" . . "1"^^ . . "C-peptid \u2013 od diagn\u00F3zy ke klinice"@cs . "C-peptid \u2013 od diagn\u00F3zy ke klinice"@cs . "V" . "12" . "1"^^ . . "http://www.internimedicina.cz/artkey/int-201112-0005_C-peptid_8211_od_diagnozy_ke_klinice.php" . "1212-7299" . "C-peptid \u2013 od diagn\u00F3zy ke klinice" . . "Sola\u0159, Svatopluk" . "RIV/00216208:11110/11:9069" . . "13" . "C-peptide is a linker between the A- and the B- chains of insulin and, following enzymatic breakdown, is released into the circulation as a 31-amino acid chain in an equimolar amount with insulin. Serum C-peptide level in the plasma is independent of the administration of exogenous insulin and does not interfere with autoantibodies that are formed against it; therefore, for diagnostic purposes, its determination is much more reliable and accurate than that of insulin. Originally used only in diagnosing, C-peptide is currently known for its endogenous effects. C-peptide may affect the degree and extent of vascular and nervous complications, its higher level prevents endothelial dysfunction and it also has analgesic effects. These direct and indirect effects give rise to considerations about possible therapeutic use. In the year 2010, authorities in the field of diabetes published new recommendations for the diagnosis and screening that reflect the global pandemic of this disease, including the incidenc"@en . . "C-peptide; insulin; diagnosis; endogenous effects; screening"@en . . "[E704E99BE252]" . "Intern\u00ED medic\u00EDna pro praxi" . . "C-peptid \u2013 od diagn\u00F3zy ke klinice" . "11110" . "C-peptid je spojovac\u00ED m\u016Fstek A a B \u0159et\u011Bzce inzulinu a je po enzymatick\u00E9m roz\u0161t\u011Bpen\u00ED vylu\u010Dov\u00E1n v podob\u011B 31 aminokyselinov\u00E9ho \u0159et\u011Bzce do ob\u011Bhu v ekvimol\u00E1rn\u00EDm mno\u017Estv\u00ED s inzulinem. S\u00E9rov\u00E1 hladina C-peptidu v plazm\u011B je nez\u00E1visl\u00E1 na pod\u00E1n\u00ED exogenn\u00EDho inzulinu a neinterferuje ani s autoprotil\u00E1tkami, kter\u00E9 se proti n\u011Bmu vytv\u00E1\u0159\u00ED, a proto je pro diagnostick\u00E9 \u00FA\u010Dely jeho stanoven\u00ED, oproti inzulinu, mnohem spolehliv\u011Bj\u0161\u00ED a p\u0159esn\u011Bj\u0161\u00ED. Toto p\u016Fvodn\u00ED jedin\u00E9 vyu\u017Eit\u00ED C-peptidu v diagnostice dnes dopl\u0148uje znalost o jeho endogenn\u00EDch \u00FA\u010Dinc\u00EDch. C-peptid m\u016F\u017Ee ovliv\u0148ovat stupe\u0148 a m\u00EDru rozvoje c\u00E9vn\u00EDch a nervov\u00FDch komplikac\u00ED, jeho vy\u0161\u0161\u00ED hladina br\u00E1n\u00ED endoteli\u00E1ln\u00ED dysfunkci a m\u00E1 i analgetick\u00E9 \u00FA\u010Dinky. Tyto p\u0159\u00EDm\u00E9 a nep\u0159\u00EDm\u00E9 efekty rozv\u00EDj\u00ED \u00FAvahy o mo\u017En\u00E9m l\u00E9\u010Debn\u00E9m vyu\u017Eit\u00ED. V roce 2010 byla autoritami v diabetologii zve\u0159ejn\u011Bna nov\u00E1 doporu\u010Den\u00ED pro diagnostiku a screening, kter\u00E1 reflektuj\u00ED celosv\u011Btovou pandemii t\u00E9to choroby, v\u010Detn\u011B incidence morbidity, vynucen\u00E9 invalidity a mortality. P\u0159ehled ukazuje i mo\u017Enosti vyu\u017Eit\u00ED C-peptidu" . . "192157" . .